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SUMMARY AT A GLANCE 
We aimed to reveal the prevalence and characteristics of OHS in Japan at present. The 
prevalence of OHS in obese OSA was approximately the same as in Western patients 
despite the much lower BMI compared with Westerns. Moreover, DLco/VA, firstly 






Background and objective: The prevalence of obesity hypoventilation syndrome (OHS) 
was said to be 9% in patients with obstructive sleep apnoea (OSA) in Japan. However, 
the definition of OSA in that previous study was not an apnoea-hypopnoea index (AHI) 
≥ 5/h but ≥ 20/h while under continuous positive airway pressure (CPAP) treatment. 
Therefore, the prevalence of OHS in OSA has not been well known in Japan as well as 
in other Asian countries. Our study objectives were to investigate the characteristics of 
Asian patients with OHS. 
Methods: Investigated were 981 participants consecutively hospitalized for suspected 
OSA. At least 90% of them were from urban areas, including 162 with obese OSA 
(body mass index (BMI) ≥ 30 kg/m2 and AHI ≥ 5/h).  
Results: The prevalence of OHS (BMI 36.7±4.9 kg/m2) in OSA and that in obese OSA 
were 2.3% and 12.3%, respectively. Multiple regression analysis revealed that 
independent of age and BMI, arterial oxygen pressure (contribution rate (R2) =7.7%), 
4% oxygen desaturation index (R2=8.9%), carbon monoxide diffusing capacity/alveolar 
volume (DLco/VA) (R2=8.3%), which was firstly reported in this study, and hemoglobin 
concentration (R2=4.9%) as well as waist circumference (R2=4.9%) were independently 
associated with arterial carbon dioxide pressure. With 12.3±4.6 months of CPAP 
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treatment, more than 60% of OHS patients no longer had hypercapnia. 
Conclusions: The prevalence of OHS in OSA in Japan was not 9% but 2.3%. The mean 
BMI of patients with OHS in Japan was lower than that in Western countries (36.7 
kg/m2 vs. 44.0 kg/m2).  
 
Key words: diffusion capacity, hypercapnia, hypoventilation, obesity, sleep apnoea.  
 




A LIST OF ABBREVIATIONS   
A-aDO2, alveolar-arterial oxygen pressure difference  
AHI, apnoea-hypopnoea index 
BMI, body mass index 
BNP, brain natriuretic peptide 
COPD, chronic obstructive pulmonary disease 
CPAP, continuous positive airway pressure 
CRP, C-reactive protein 
DLco, carbon monoxide diffusing capacity 
ERV, expiratory residual volume 
ESS, Epworth Sleepiness Scale 
FEV1, forced expiratory volume in 1 second  
FRC, functional residual capacity 
FVC, forced vital capacity 
Hb, hemoglobin 
HbA1c, hemoglobin A1c 
HCO3-, bicarbonate 
HDL-Chol, high density lipoprotein cholesterol 
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HOMA-R, homeostasis model assessment of insulin resistance 
LDL-Chol, low density lipoprotein cholesterol 
NA, not applied 
ODI, oxygen desaturation index 
OHS, obesity hypoventilation syndrome 
OSA, obstructive sleep apnoea 
PaCO2, arterial carbon dioxide pressure 
PaO2, arterial oxygen pressure 
pH, potential hydrogen 
R2, contribution rate 
RBC, red blood cells 
RV, residual volume 
SD, standard deviation 
SpO2, arterial oxygen saturation 
T-Chol, total cholesterol 
TG, triglyceride 
TST, total sleep time  
VA, alveolar volume 
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In accordance with the continuing increases in rates of obesity, the incidence of obesity 
hypoventilation syndrome (OHS) has also increased. OHS is defined as the combination 
of obesity (body mass index (BMI) ≥ 30 kg/m2) and chronic daytime hypercapnia 
(arterial carbon dioxide pressure (PaCO2) ≥ 45 mmHg).1,2 In addition, the definition of 
OHS in previous reports included hypoxemia (arterial oxygen pressure (PaO2) < 70 
mmHg).3,4 It was reported that the prevalence of OHS in patients with obese obstructive 
sleep apnoea (OSA) was 10-20%4-6 and that 0.3-0.4% of the general population might 
have OHS.7,8 OHS is an entity distinct from OSA or simple obesity and is associated 
with greater morbidity and mortality than either.9 Because of cephalometric differences, 
OHS may occur at a lower BMI in Asians than in Western individuals, as does OSA.10-12 
In Japan, Akashiba et al.10 reported using data from 7 hospitals showing that OSA with 
hypercapnia was present in 9% of patients with OSA (apnoea-hypopnoea index (AHI) ≥ 
20 /h) who were under continuous positive airway pressure (CPAP) treatment and in 
32% of patients with obese OSA (AHI ≥ 20 /h and BMI ≥ 30 kg/m2) who were 
receiving CPAP treatment. Therefore, there have been no data about OHS (BMI ≥ 30 
kg/m2 and PaCO2 ≥ 45 mmHg) in a large number of Asians, which definition was based 
on that in Western countries.  
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Despite several reports that examined the determinants of PaCO2, diffusion capacity 
from pulmonary function tests, the disturbance of which is one factor related to 
hypoxemia, was not measured in previous reports, although hypercapnia with 
hypoxemia is an important issue in patients with OHS4 because hypoxemia is 
uncommon in patients with simple OSA.4 
We hypothesized that the prevalence of OHS in individuals with OSA in Japan was 
not as high as 9% as previously reported10, and that in addition to obesity, other factors 
were independently associated with PaCO2. We also hypothesized that diffusion 
capacity, which was not investigated in previous reports, may be an important factor in 
OHS because it is considered that patients with OHS have a greater degree of 




METHODS (Details are in Online Supporting Information.) 
Participants 
Participants were consecutively hospitalized in Kyoto University Hospital from October 
2008 to September 2012 for a detailed examination for suspected OSA (Fig. 1). Owing 
to snoring, witnessed apnoea, daytime sleepiness, obesity, etc. about 60% were 
self-referrals and 40% were secondary referrals. Our hospital is located in the 7th largest 
urban city (Kyoto) in Japan and adjacent to the 3rd (Osaka) and 6th (Kobe) largest cities. 
From the address of the participants, at least 90% were from urban areas. We based the 
diagnosis of OHS on a BMI ≥ 30 kg/m2 and PaCO2 ≥ 45 mmHg and that of hypoxemic 
OHS on a BMI ≥ 30 kg/m2, PaCO2 ≥ 45 mmHg, and PaO2 < 70 mmHg.  
The study protocol was approved by the Kyoto University Graduate School and 
Faculty of Medicine Ethics Committee (approved number: E566). Informed consent 
was obtained from all patients. This clinical trial was registered in UMIN (reference 
number: UMIN000001931).   
  
Polysomnography 
Diagnosis of OSA was confirmed by polysomnography (SomnoStar pro, Cardinal 
Health, Dublin, OH, USA) as previously reported.13 Apnoea was defined as the 
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complete cessation of airflow for at least 10 seconds and hypopnoea as a decrease in 
airflow of 50% or more lasting for at least 10 seconds, accompanied by oxygen 
desaturation of ≥ 3% or an arousal.14 The 4% oxygen desaturation index (ODI) was 
determined by the frequency of desaturations of ≥ 4% per hour. 
 
Assessment of pulmonary function 
Pulmonary function tests were performed using a standard spirometer, according to the 
recommended method.15 The values for carbon monoxide diffusing capacity (DLco) 
adjusted for hemoglobin were calculated.16 
 
Laboratory analyses of blood 
Arterial blood for blood gas analysis was drawn under room air conditions just before 
polysomnography started at night with the participants in the supine position that was 
maintained for 20 minutes before arterial blood was drawn.  
 
Statistical analysis 
Baseline characteristics are expressed as mean values with standard deviation (SD) or 
numbers. Normality and homogeneity of variance assumptions were checked before 
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further analyses. After normality testing, all the variables were treated as parametric. 
Unpaired t-tests and chi-square tests were used to compare the backgrounds of two 
groups. In addition, the analysis of a covariance model adjusted for waist circumference 
was used to compare two groups. Relationships between two sets of continuous data 
were analyzed by Pearson’s correlation coefficient tests and those of dichotomous data 
were analyzed by Spearman rank correlation coefficient. P values < 0.05 were 
considered to be statistically significant. Multiple regression analyses, with a P value < 
0.10 for entry into the models, were performed to identify variables that could be best 
associated with PaCO2. Statistical analyses were performed using Statview 5.0 (SAS 
Institute, Inc. Cary, NC, USA).  
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RESULTS (Details are in Online Supporting Information.) 
Characteristics of participants 
Of the 1127 patients assessed for suspected OSA, 981 participants (673 males and 308 
females) were entered into the study (Fig. 1). In the excluded groups, there were 2 
non-obese sever chronic obstructive pulmonary disease (COPD) patients (Fig. 1). 
Table 1 shows characteristics of the 981 participants. Among them, 880 (89.7%) had 
OSA (AHI ≥ 5 /h). Ninety-two (10.5%) OSA patients had hypercapnia. The prevalence 
of OHS (BMI ≥ 30 kg/m2 and PaCO2 ≥ 45 mmHg) among the study participants was 
2.1% (21/981), and that of OHS among participants with OSA was 2.3% (20/880). 
More than 95% (20/21) of the OHS patients had OSA (AHI ≥ 5 /h).  
 
Comparison between OHS and non-OHS in obese OSA 
Table 2 shows the comparison between the 162 obese OSA (BMI ≥ 30 kg/m2 and AHI ≥ 
5 /h) with and without OHS. Of patients with obese OSA, 20 (12.3%) had OHS.  
 
Prevalence of OHS regarding the degree of obesity  
The prevalence of OHS in the patients with a BMI 30-34.9 kg/m2 was 6.8%, and that 
with a BMI ≥ 35 kg/m2 was 25.0% (Fig. 2). Only 6 (3.6%) of 169 patients with a BMI ≥ 
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30 kg/m2 had a BMI ≥ 40 kg/m2. Based on the estimate by the Ministry of Health, Labor 
and Welfare in Japan, individuals (age ≥ 15 y) with a BMI ≥ 30 kg/m2 comprised 3.9% 
of the Japanese population.17 We estimated that about 0.48% of the population in Japan 
might have OHS. When we compared OHS patients with and without hypoxemia, DLco 
was significantly lower in the hypoxemic OHS patients (79.7±19.0%) than in those 
without hypoxemia (96.4±8.4%) (P = 0.033) (Table S1). 
 
Multiple regression analysis to identify independent determinants of CO2 
accumulation in obese OSA 
PaCO2 had significant and independent associations not only with waist circumference 
(contribution rate (R2) = 4.9%) but also with PaO2 (R2 = 7.7%), 4%ODI (R2 = 8.9%), 
DLco/ alveolar volume (VA) (R2 = 8.3%) and hemoglobin (R2= 4.9%) (Table 3 and Fig. 
3). Among those variables, strong co-linearity was not found (Table S3). When using 
AHI, instead of 4%ODI, PaCO2 had significant and independent associations with the 
same factors. 
 
Improvements in arterial blood gas after CPAP treatment  
Of the 20 OHS patients with OSA, 18 OHS patients were introduced to CPAP treatment. 
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Three of the 18 patients chose to discontinue CPAP treatments and one patient refused 
to provide arterial blood samples for blood gas analyses after CPAP treatment. Finally, 
we assessed data on 14 OHS patients with OSA that were obtained before and after 
CPAP treatment (Fig. S1). 
In the 14 patients, PaCO2 significantly improved after more than 6 months of CPAP 
treatment (treatment duration; 12.3±4.6 mo) (Table 4). In 12 of the 14 OHS patients 
(85.7%), PaCO2 improved and more than 60% of those patients (9/14) had PaCO2 < 45 
mmHg. Differences between before and after CPAP treatment in 4%ODI and those in 
PaCO2 were significantly correlated (r = 0.69, P = 0.005) (Fig. 4A).     
Objective data on adherence indicated that CPAP adherence among the 14 patients 
was 3.0 h/day. Differences between before and after CPAP treatment in PaCO2 and 
CPAP adherence estimated for the month when arterial blood was drawn were 





In our study, the prevalence of OHS in OSA (AHI ≥ 5 /h) was not 9%10 but 2.3%, while 
Akashiba et al. used a different definition (AHI ≥ 20 /h on CPAP treatment)10. Also, the 
prevalence of OHS in obese OSA (12.3%) was estimated to be the same as in the West, 
but the mean BMI in patients with OHS in our study (36.7 kg/m2) was lower than that in 
Western countries (44 kg/m2).5,18 Multiple regression analysis revealed that, in addition 
to waist circumference, DLco/VA and hemoglobin level, PaO2 while awake and 4%ODI 
were independently associated with PaCO2.  
It is said that the prevalence of OHS in patients with OSA in Japan was 9%10 and 
several reviews quoted that percentage as the prevalence of OHS in OSA in an Asian 
country (Japan). In addition to the fact that the participants were not consecutively 
enrolled and the data were acquired 10 years ago, it is highly important to consider that 
the definition of OHS in OSA in that report was not BMI ≥ 30 kg/m2, AHI ≥ 5 /h and 
PaCO2 ≥ 45 mmHg, which is usually recognized as the definition of OHS in OSA, but 
AHI ≥ 20 /h under CPAP treatment and PaCO2 ≥ 45 mmHg. From our consecutive data 
from one hospital in Japan, the prevalence of OHS in OSA (AHI ≥ 5 /h) was 2.3%. 
Although the prevalence of OHS in individuals with OSA was lower than previously 
reported,5 that of OHS in obese OSA (BMI ≥ 30 kg/m2 and AHI ≥ 5 /h) was 12.3%, 
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which was close to the frequency cited in previous reports.5,6,18  
It has been reported that individuals with a BMI ≥ 30 kg/m2 comprised 3.9% of the 
Japanese population17 and 30.3% of the U.S.A population.19 Therefore, although the 
prevalence of OHS in patients with BMI ≥ 30 kg/m2 was the same as in Western 
populations, its prevalence among our study patients increased more steeply with 
elevations in BMI than among Western populations (Fig. 2). Our data suggested that 
OSA could easily develop into OHS in Asians as they become more obese, as OSA 
itself develops in Asians with a low BMI.11,12,20 Young et al.12 reported that the 
craniofacial and upper airway structure had an important role in OSA occurrence and 
might be particularly significant in Asians. These craniofacial and upper airway 
characteristics in Asians may result in a worse AHI or 4%ODI at a relative lower BMI 
than in Western individuals. Thus, hypercapnia could be worse in Asian patients with a 
lower BMI as well as OSA could.  
Kaw et al. found that severity of obesity, severity of OSA, and pulmonary restrictive 
impairment were risk factors for hypercapnia.7 Two previous reports from Japan21,22 
showed that not obesity but OSA related to AHI, nocturnal desaturation and pulmonary 
impairment play major roles in the cause of hypercapnia as indicated by some of the 
parameters in this study. In this study, 10.5% (92/880) of the OSA patients (BMI 26.2 
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kg/m2) had hypercapnia, while 13.7% (168/1227) of the OSA patients (BMI 28.6 kg/m2) 
had hypercapnia in a previous study.22 Although the prevalence of hypercapnia in OSA 
patients differed between studies, the characteristics of the previous cohort22 were 
almost the same as this study. Since the mean BMI in the former cohort22 was slightly 
larger than in ours (28.6 kg/m2 vs. 26.2 kg/m2), the prevalence of hypercapnia in OSA 
patients was slightly higher than in ours (13.7% vs. 10.5%). It may indicate that the 
severity of OSA might play a larger role in Japanese patients than in Western 
populations.          
This is the first report to reveal that DLco/VA was a significant determinant of 
hypercapnia in OHS. Obese patients have a high cardiac output and elevated total and 
central blood volume, which increase central circulatory congestion and capillary blood 
volume and result in elevations in DLco/VA.23-25 In addition, the low lung volume in the 
patients with OHS which was reported previously9,26 also might induce high DLco/VA. 
However, it should be noted that DLco/VA might produce a large number of false 
negative results, particularly in those with a low lung volume. In addition, whether this 
is an epiphenomenon or represents a genuine aspect of pathophysiology is unclear and 
needs further investigation.  
Elevated hemoglobin in the OHS patients might be due to severe sustained 
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desaturation during sleep (SpO2 < 90 (% total sleep time)). Recent data showed that 
sustained hypoxia induced increases in hemoglobin through hypoxia inducible 
factor-1.27 Further research on the relationship between secondary polycythemia and 
hypercapnia in OSA should be done in the future.  
Our results also implied that abdominal obesity, as assessed by waist circumference, 
has an independent effect on hypoventilation as previously reported.28 Abdominal 
obesity with increased waist circumference effected a restrictive respiratory impairment, 
which was associated with a reduction in PaO2,29,30 inducing daytime hypoxemia.31 Our 
results could be important because hypoxemia induced by hypercapnia might worsen 
the hypercapnia and vice versa.  
In our study, 4%ODI was independently associated with PaCO2 (Table 3). In addition, 
the degrees of improvement in the 4%ODI with CPAP treatment were significantly 
associated with those in PaCO2 levels (Fig. 4A). These data indicate that OSA induced 
worse awake PaCO2 levels in patients with OSA. 
In our study, obese OSA patients with OHS had a larger waist circumference, 
presenting a greater restrictive load, than those without OHS (Table 2) although there 
was no difference in neck circumference. In this study, OHS patients seemed to be more 
amenable to correction of PaCO2 levels by CPAP treatment, which might be due to a 
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lesser restrictive load with a lower BMI compared to the higher BMI in Western 
patients with OHS, along with the correction of upper airway collapse. 
Our study had some limitations. First, it came from a single center. Second, the 
number of patients with OHS was small, although the analysis included a large number 
of patients (n = 981). Therefore, the conclusions should be viewed with caution. Third, 
OSA can coexist with COPD and causes greater oxygen desaturation and potential 
pulmonary hypertension. Thus, the true prevalence of OHS may be underestimated by 
excluding patients with COPD. However, in this study, since there were only 2 severe 
COPD patients and they were not obese, the effects of COPD with hypercapnia on the 
results of this study were slight.   
In conclusion, the prevalence of OHS in Japan seems to be the same as in the West, 
even though the degree of obesity is less. In our patients with OHS, both sleep apnoea 
and diurnal oxygenation were independently associated with PaCO2 in addition to 
increases in DLco/VA. In our study, contribution rates of PaO2 or 4%ODI to the 
variations in PaCO2 were lower than in previous reports, which might be due to racial 
differences among participants. For this reason, further studies are needed to examine 
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FIGURE LEGENDS  
Figure 1 Study flowchart 
OSA, obstructive sleep apnoea. 
Figure 2 Prevalence of OHS according to the degree of obesity 
OHS, obesity hypoventilation syndrome; BMI, body mass index. 
●：results from our study, ○：results from the report by Mokhlesi et al5, ■：results from 
the report by Laaban et al6 
Figure 3 Independent contribution rate of each component to PaCO2 
PaCO2, arterial carbon dioxide pressure; PaO2, arterial oxygen pressure; ODI, oxygen 
desaturation index; DLco/VA, carbon monoxide diffusing capacity/alveolar volume; Hb, 
hemoglobin. 
■: waist circumference,   : PaO2,  :: 4%ODI,    : DLco/VA,   : Hb, □: others 
Figure 4  
A Relationship between differences between before and after CPAP treatment in PaCO2 
and those in 4%ODI  
r means correlation coefficient. 
CPAP, continuous positive airway pressure; PaCO2, arterial carbon dioxide pressure; 
ODI, oxygen desaturation index.  
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B Relationship between differences between before and after CPAP treatment in PaCO2 
and CPAP adherence 
r means correlation coefficient. 





























Table 1 Characteristics of study participants 
 All participants 
Number (n) 981 
Men : Women 673 : 308 
OHS : non-OHS 21: 960 
Age (years) 59 ± 15 
BMI (kg/m2) 25.8 ± 5.0 
Neck circumference (cm) 38.4 ± 4.3 
Waist circumference (cm) 92.2 ± 13.3 
Waist-hip ratio 0.99 ± 0.65 
Pack years of smoking 18.6 ± 28.7 
ESS score 9.7 ± 5.3 
Arterial blood gas  
pH 7.42 ± 0.03 
PaCO2 (mmHg) 40.7 ± 3.8 
PaO2 (mmHg) 83.4 ± 10.9 
HCO3- (mEq/l) 25.8 ± 1.9 
A-aDO2 (mmHg) 15.7 ± 11.7 
Sleep data  
Severity of OSA 
(non/mild/moderate/severe) 
101/179/277/424 
AHI (/h) 30.0 ± 21.5 
Arousal index (/h) 19.2 ± 12.3 
4% ODI (/h) 21.7 ± 21.9 
SpO2<90 (%TST) 11.7 ± 19.9 
minimum SpO2 (%) 81.1 ± 9.4 
mean SpO2 (%) 93.9 ± 3.1 
Pulmonary function  
FVC (% predicted) 106.8 ± 18.1 
FEV1/FVC (%) 77.5 ± 8.4 
ERV (% predicted) 94.7 ± 47.6 
FRC (% predicted) 108.0 ± 50.9 
RV (% predicted) 115.4 ± 42.5 
DLco (% predicted) 80.9 ± 18.2 
DLco/VA (% predicted) 94.9 ± 19.4 
Venous blood data  
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Glucose (mg/dl) 104 ± 29 
HbA1c (%) 5.7 ± 1.0 
TG (mg/dl) 133 ± 94 
T-Chol (mg/dl) 190 ± 39 
LDL-Chol (mg/dl) 110 ± 47 
HDL-Chol (mg/dl) 51 ± 14 
  
Data are presented as mean ± standard deviation (SD) or numbers. SpO2<90 (%TST) 
means the percentage of the total sleep time with SpO2 < 90%. 
OHS, obesity hypoventilation syndrome; BMI, body mass index; ESS, Epworth 
Sleepiness Scale; pH, potential hydrogen; PaCO2, arterial carbon dioxide pressure; 
PaO2, arterial oxygen pressure; HCO3-, bicarbonate; A-aDO2, alveolar-arterial oxygen 
pressure difference; OSA, obstructive sleep apnoea; AHI, apnoea-hypopnoea index; 
ODI, oxygen desaturation index; SpO2, arterial oxygen saturation; TST, total sleep time; 
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; ERV, 
expiratory residual volume; FRC, functional residual capacity; RV, residual volume; 
DLco, carbon monoxide diffusing capacity; VA, alveolar volume; HbA1c, hemoglobin 
A1c; TG, triglyceride; T-Chol, total cholesterol; LDL-Chol, low density lipoprotein 





Table 2 Comparison of obese OSA patients with and without OHS 
 All patients OHS Non-OHS P-value † P-value 
Number (n (%)) 162 20 (12.3%) 142 (87.7%)   
Men : Women 103 : 59 11 : 9 92 : 50 0.46 - 
Age (years) 53 ± 13  50 ± 12 54 ± 13 0.22 0.60 
BMI (kg/m2)  34.1 ± 4.1 36.7 ± 4.9 33.7 ± 3.8 0.002 - 
Neck circumference (cm) 42.5 ± 3.9 42.4 ± 4.6 42.6 ± 3.8 0.91 - 
Waist circumference (cm)  110.9 ± 12.6 117.8 ± 13.1  110.0 ± 12.2 0.010 NA 
Waist-hip ratio 1.1 ± 1.6 1.0 ± 0.04 1.2 ± 1.71 0.70 - 
Pack years of smoking 20.6 ± 33.3 10.9 ± 22.0 22.1 ± 34.5 0.16 0.89 
ESS score  10.4 ± 5.6 10.6 ± 6.8 10.3 ± 5.4 0.86 0.69 
Arterial blood gas      
pH 7.42 ± 0.03 7.39 ± 0.03 7.42 ± 0.03 < 0.001 0.78 
PaCO2 (mmHg)  41.2 ± 4.4 49.0 ± 5.5 40.2 ± 2.8 < 0.001 0.014 
PaO2 (mmHg)  77.5 ± 10.2 72.6 ± 11.4 78.2 ± 9.8 0.021 0.77 
HCO3- (mEq/l)  25.8 ± 2.1 28.6 ± 2.4 25.4 ± 1.7 < 0.001 0.12 
A-aDO2 (mmHg) 21.0 ± 11.2 15.9 ± 10.2 21.7 ± 11.2 0.029 0.52 
Sleep data      
Severity of OSA 
(mild/moderate/severe) 
24/36/102 0/7/13 24/29/89 0.12 - 
AHI (/h) 44.4 ± 28.0 61.6 ± 40.0 42.0 ± 25.1 0.003 0.048 
Arousal index (/h)  23.5 ± 17.6 32.7 ± 29.0 22.2 ± 15.1 0.013 0.010 
4% ODI (/h)  34.7 ± 28.6 56.7 ± 42.6 31.6 ± 24.8 < 0.001 0.039 
SpO2<90 (%TST)  23.5 ± 28.2 45.5 ± 37.5 20.4 ± 25.4 < 0.001 0.50 
minimum SpO2 (%)  76.0 ± 10.7 66.5 ± 13.8 77.4 ± 9.6 < 0.001 0.39 
mean SpO2 (%)  91.9 ± 4.2 88.1 ± 7.1 92.5 ± 3.3 < 0.001 0.16 
Pulmonary function      
FVC (% predicted) 101.8 ± 18.2 92.8 ± 19.9 103.0 ± 17.7 0.031 0.33 
FEV1/FVC (%)  79.2 ± 8.2 80.0 ± 7.1   79.1 ± 8.3 0.66 0.32 
ERV (% predicted)  60.7 ± 35.3 51.7 ± 42.8 61.9 ± 34.2 0.27 0.013 
FRC (% predicted) 126.5 ± 109.0 175.1 ± 121.9 120.1 ± 106.0 0.057 0.11 
RV (% predicted) 117.8 ± 36.5 116.8 ± 25.1 117.9 ± 37.8 0.90 0.75 
DLco (% predicted) 85.8 ± 16.4 91.2 ± 17.4 85.1 ± 16.2 0.16 0.55 
DLco* (% predicted) 85.8 ± 15.2 89.1 ± 16.0 85.4 ± 15.2 0.36 0.46 
DLco/VA (% predicted) 104.1 ± 19.6 118.5 ± 17.6 102.2 ± 19.1 0.002 0.25 
DLco/VA* (% predicted) 104.1 ± 18.6 115.9 ± 16.1 102.6 ± 18.5 0.007 0.19 
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Venous blood data      
WBC (×103/μl) 6.45 ± 1.98 6.67 ± 2.56 6.42 ± 1.89 0.61 0.55 
RBC (×106/μl) 4.76 ± 0.55 4.93 ± 0.54 4.74 ± 0.55 0.16 0.46 
Hb (g/dl) 14.3 ± 2.0 14.9 ± 1.7 14.2 ± 2.1 0.17 0.44 
Platelets (×103/μl) 221 ± 62 197 ± 35 224 ± 64 0.059 0.62 
Glucose (mg/dl) 115 ± 38 108 ± 30 116 ± 40 0.41 0.57 
HbA1c (%)  6.1 ± 1.3 6.2 ± 1.4 6.1 ± 1.3 0.86 0.21 
Insulin (μU/ml) 18.1 ± 16.3 15.3 ± 9.2 18.5 ± 17.1 0.45 0.98 
HOMA-R 5.1 ± 5.1 4.0 ± 2.2 5.3 ± 5.4 0.33 0.92 
TG (mg/dl)  171 ± 137 151 ± 102 174 ± 141 0.51 0.84 
T-Chol (mg/dl)  197 ± 42 205 ± 47 196 ± 42 0.44 0.15 
LDL-Chol (mg/dl)  117 ± 32 126 ± 36 116 ± 31 0.19 0.056 
HDL-Chol (mg/dl)  48 ± 11 49 ± 9  48 ± 12 0.68 0.90 
BNP (pg/dl)  29.0 ± 54.8 25.3 ± 26.0  29.5 ± 57.7 0.77 0.56 
CRP (mg/dl) 0.25 ± 0.30 0.34 ± 0.36 0.23 ± 0.29 0.20 0.24 
Fibrinogen (mg/dl)  293 ± 72 315 ± 67 290 ± 72 0.18 0.63 
Data are presented as mean ± SD or numbers (percent). SpO2<90 (%TST) means the 
percentage of the total sleep time with SpO2 < 90%. † P-value means the values after 
adjustment for waist circumference by analysis of covariance. DLco* (% predicted) and 
DLco/VA* (% predicted) are values for DLco (% predicted) and DLco/VA (% 
predicted) adjusted for values for hemoglobin. 
OSA, obstructive sleep apnoea; OHS, obesity hypoventilation syndrome; BMI, body 
mass index; NA, not applied; ESS, Epworth Sleepiness Scale; pH, potential hydrogen; 
PaCO2, arterial carbon dioxide pressure; PaO2, arterial oxygen pressure; HCO3-, 
bicarbonate; A-aDO2, alveolar-arterial oxygen pressure difference; AHI, 
apnoea-hypopnoea index; ODI, oxygen desaturation index; SpO2, arterial oxygen 
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saturation; TST, total sleep time; FVC, forced vital capacity; FEV1, forced expiratory 
volume in 1 second; ERV, expiratory residual volume; FRC, functional residual 
capacity; RV, residual volume; DLco, carbon monoxide diffusing capacity; VA, 
alveolar volume; WBC, white blood cells; RBC, red blood cells; Hb, hemoglobin; 
HbA1c, hemoglobin A1c; HOMA-R, homeostasis model assessment of insulin 
resistance; TG, triglyceride; T-Chol, total cholesterol; LDL-Chol, low density 
lipoprotein cholesterol; HDL-Chol, high density lipoprotein cholesterol; BNP, brain 







Table 3 Stepwise multiple regression analysis to reveal independent associated factors 
with PaCO2 
 β r P-value R2 (%) 
Waist circumference (cm) 0.19 0.25 0.010 4.9 
PaO2 (mmHg) -0.25 -0.31 0.001 7.7 
4%ODI (/h) 0.22 0.41 0.008 8.9 
DLco/VA (% predicted) 0.24 0.35 0.002 8.3 
Hb (g/dl) 0.17 0.29 0.026 4.9 
Cumulative R2    34.6 
In the stepwise multiple regression analyses, age, BMI, waist circumference, PaO2, 
4%ODI, SpO2 < 90 (%TST), FVC (% predicted), DLco/VA (% predicted), WBC and 
Hb were used as variables. Then, age, BMI, SpO2 < 90 (%TST), FVC (% predicted) and 
WBC were excluded because of insignificance. 
β means standard regression coefficient, r means correlation coefficient and R2 indicates 
the contribution rate. SpO2 < 90 (%TST) means the percentage of the total sleep time 
with SpO2 < 90%. 
PaCO2, arterial carbon dioxide pressure; PaO2, arterial oxygen pressure; ODI, oxygen 
desaturation index; DLco/VA, carbon monoxide diffusing capacity/alveolar volume; Hb, 
hemoglobin; BMI, body mass index; SpO2, arterial oxygen saturation; TST, total sleep 




Table 4 Anthropometry, arterial blood gas and sleep data in OHS before and after 
CPAP treatment 
 Before 
(n = 14) 
After 
(n = 14) 
P-value 
BMI (kg/m2)  37.0 ± 5.6  35.8 ± 4.9 0.12 
pH 7.39 ± 0.03  7.41 ± 0.02 0.039 
PaCO2 (mmHg)  49.5 ± 6.3 43.8 ± 2.9 0.010 
PaO2 (mmHg)  73.6 ± 13.0 77.8 ± 9.0 0.24 
HCO3- (mEq/l)  28.9± 2.7   27.1 ± 1.9 0.021 
A-aDO2 (mmHg)  14.2 ± 11.5  17.2 ± 7.0 0.36 
AHI (/h) 66.1 ± 42.9 8.2 ± 5.5 < 0.001 
4%ODI (/h) 60.4 ± 46.5 4.4 ± 3.2 < 0.001 
SpO2 < 90 (%TST) 50.2± 42.6 6.8±21.1 0.001 
Data are presented as mean ± SD. SpO2 < 90 (%TST) means the percentage of the total 
sleep time with SpO2 < 90%. 
Values for AHI, 4%ODI and SpO2 < 90 (%TST) after CPAP treatment were obtained 
from data of a repeated polysomnography in a laboratory setting after 2 days of CPAP 
usage. 
OHS, obesity hypoventilation syndrome; CPAP, continuous positive airway pressure; 
BMI, body mass index; pH, potential hydrogen; PaCO2, arterial carbon dioxide 
pressure; PaO2, arterial oxygen pressure; HCO3-, bicarbonate; A-aDO2, alveolar-arterial 
oxygen pressure difference; AHI, apnoea-hypopnoea index; ODI, oxygen desaturation 
index; SpO2, arterial oxygen saturation; TST, total sleep time. 
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